Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Earnings for Embecta Corp. (EMBC)
Earnings in 2023 (TTM): $105.7 M
According to Embecta Corp.'s latest financial reports the company's current earnings (TTM) are $105.7 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Embecta Corp.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $105.7 M | $70.4 M |
| 2022 | $256.6 M | $223.6 M |
| 2021 | $495 M | $414.8 M |
| 2020 | $485.8 M | $427.6 M |
| 2019 | $500 M | $432 M |